Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Medigus: Successful Three-Year Follow-Up Data of the SRS(TM) Pivotal Study in Indiana University Will be Presented at the Digestive Disease Week in Orlando

May 16, 2013

OMER, Israel, May 16, 2013 /PRNewswire/ –

Medigus Ltd. (TASE:MDGS), a leading medical device company dedicated to the
development of innovative endoscopic procedures and technologies, will be presenting the
successful three year follow-up data of the SRS(TM) pivotal study at the Digestive Disease
Week in Orlando on May 18-21st 2013.

(Logo:
http://photos.prnewswire.com/prnh/20130313/601331 )

The study that was conducted in Indiana University, a leading U.S medical center,
clearly indicates that the majority of patients treated by the endoscopic system SRS(TM)
were able to stop taking daily PPl (drugs that have a long-lasting reduction effect of
gastric acid production) in the third year post the procedure.

This three year study is presented shortly after five-year follow-up results of a
pilot study of the SRS(TM) endoscopic system for the treatment of Gastroesophageal Reflux
Disease (GERD). The pilot study had been conducted at the Deenanath Mangeshkar Hospital
and Research Center in Pune, India in 2007.

As reported by the lead investigator of the pilot study Dr. Amol Bapaye, the five-year
follow-up results are similar to those produced by a laparoscopic-surgical procedure for
the treatment of GERD in the same timeframe.

The endoscopic system SRS(TM) performs a minimally-invasive treatment of
Gastroesophageal Reflux Disease (GERD), one of the most common chronic diseases globally.
The system which includes a disposable surgical endoscope, performs an anterior
fundoplication in lieu of the current surgical procedure, without incisions and opening
the abdominal cavity.

The SRS(TM) offers a treatment by an independent device that doesn’t require any
additional components during the procedure. The operation is rather intuitive and can be
performed by one surgeon or GI. In addition, the procedure can be conducted in the
endoscopy suite to ensure the saving of operation room time.

Dr. Elazar Sonnenschein, Medigus CEO commented: “Medigus has developed an innovative
solution to treat GERD and we’re excited to present the excellent supportive data from our
three year study and five-year follow-up. It is rewarding to watch patients that no longer
need to rely on daily use of drugs to support their routine. We strongly believe that our
minimal invasive solution will replace many of the unnecessary surgeries which are
performed today.”

The Digestive Disease Week (DDW) is the largest and most prestigious conference in the
world for the Gastrointestinal Infection (GI) professional community and an average of
15,000 medical professionals from around the world attend this meeting every year.

About Medigus Ltd.

Medigus (TASE: MDGS) is a medical device company headquartered in Omer, Israel,
specializing in developing innovative endoscopic procedures and devices. Medigus is a
pioneer developer of a unique proprietary endoscopic device for the treatment of GERD, one
of the most common chronic diseases in the western world.

Medigus has an advanced technology platform that includes all necessary elements for
performing a wide range of endoscopic procedures. The platform includes various types of
rigid, semi-flexible and flexible video endoscopes, as well as respective endoscopy
suites.

For more information please visit: http://www.medigus.com

        Contact:
        Miri Segal-Scharia
        Hayden/ MS-IR LLC
        Tel: +1-917-607-8654
        msegal@ms-ir.com

    Photo: 

http://photos.prnewswire.com/prnh/20130313/601331

SOURCE Medigus Ltd


Source: PR Newswire